In:
Alimentary Pharmacology & Therapeutics, Wiley, Vol. 53, No. 12 ( 2021-06), p. 1309-1316
Abstract:
Identification of risk factors for the development of hepatocellular carcinoma (HCC) after a sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection is urgently needed for HCC surveillance. Aims To evaluate whether the presence of non‐hypervascular hypointense nodules (NHHNs) depicted by gadolinium‐ethoxybenzyl‐diethylenetriamine pentaacetic acid‐enhanced magnetic resonance imaging (EOB‐MRI) before direct‐acting antivirals (DAAs) therapy is a risk factor for de novo HCC development after SVR. Methods The presence of NHHNs was examined with EOB‐MRI before the start of DAA therapy in 383 patients with HCV infection who achieved SVR. The incidence of de novo HCC after SVR was compared between patients with versus without NHHNs. Results NHHNs were detected before DAA therapy in 32 patients (8.4%). The incidence of de novo HCC after SVR was significantly higher in patients with NHHNs than in those without (1‐, 3‐, 5‐year incidence, 9.8%, 24.2% and 41.6% vs. 0%, 1.2% and 4.4%, P 〈 0.0001). The presence of NHHNs before DAA therapy (adjusted HR, 10.86; 95% CI, 4.03‐31.64) and cirrhosis (adjusted HR, 7.23; 95% CI, 1.88‐35.85) were independently associated with a higher incidence of HCC after SVR. A higher incidence of de novo HCC after SVR remained after adjustment for age, gender, regular alcohol intake, diabetes, cirrhosis, FIB‐4 index and serum alpha‐foetoprotein with inverse probability of treatment weighting. Conclusions This study confirmed that the presence of NHHNs before DAA therapy is a strong risk factor for the development of de novo HCC after SVR.
Type of Medium:
Online Resource
ISSN:
0269-2813
,
1365-2036
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2003094-0
SSG:
15,3
Permalink
